144927-57-1

Basic information

• Product Name: ethyl 4-chloro-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate
• Synonyms: ethyl 4-chloro-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate;3-d]pyriMidine-5-carboxylate;ethyl 4-chloro-7H-pyrrolo[2;Ethyl 4-chloro-7H-pyrrolo...;ethyl 4-chloro-1H-pyrrolo[2,3-d]pyrimidine-5-carboxylate
• CAS NO: 144927-57-1
• Molecular Formula: C₉H₈ClN₃O₂
• Molecular Weight: 225.63172
• Product Categories: CHIRAL CHEMICALS;Heterocycle-Pyrimidine series
• Mol File: 144927-57-1.mol

Chemical Properties

• Melting Point: 140-141 °C
• Boiling Point: 397.056 °C at 760 mmHg
• Flash Point: 193.933 °C
• Appearance: /
• Density: 1.459 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.644
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 9.72±0.20(Predicted)
• CAS DataBase Reference: ethyl 4-chloro-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-chloro-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate(144927-57-1)
• EPA Substance Registry System: ethyl 4-chloro-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate(144927-57-1)

Safety Data

• Hazardous Substances Data: 144927-57-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 4-chloro-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate is used as a building block for the synthesis of new pharmaceutical compounds. Its structure allows for the development of drugs targeting specific cellular pathways, offering potential therapeutic benefits.
Used in Medicinal Chemistry Research:
As a chemical compound with a unique structure, ethyl 4-chloro-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate is used in medicinal chemistry research to explore its potential biological activity and evaluate its efficacy in treating various diseases and conditions.
Used in Drug Discovery:
Ethyl 4-chloro-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate serves as a starting point for drug discovery, providing a foundation for the development of new drugs with novel mechanisms of action. Further research and testing of this compound may reveal its potential uses in treating a wide range of medical conditions.

InChI:InChI=1/C9H8ClN3O2/c1-2-15-9(14)5-3-11-8-6(5)7(10)12-4-13-8/h3-4H,2H2,1H3,(H,11,12,13)

Upstream product

• 22276-95-5 5-bromo-4-chloro-7H-pyrrolo[2,3-d]pyrimidine 
• 541-41-3 chloroformic acid ethyl ester 
• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 

Downstream Products

• 1443235-93-5 ethyl 4-(3-[(2,2,2-trifluoroethyl)amino]phenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate 
• 1443235-95-7 ethyl 4-{3-[(2-methylacryloyl)amino]phenyl}-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate 
• 1443236-32-5 ethyl 4-{3-{(2-fluoroacryloyl)amino}phenyl}-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate 
• 1443236-74-5 ethyl 4-(3-[(3-chloro-1,2,4-thiadiazol-5-yl)amino]phenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate 
• 1443236-78-9 ethyl 4-(3-(2-cyanopyrimidin-4-yl)phenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate 
• 1443236-83-6 ethyl 4-(3-(3-(cyanomethyl)ureido)phenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate 
• 1443236-85-8 ethyl 4-{3-[(ethenylsulfonyl)amino]phenyl}-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate 
• 1443237-59-9 ethyl 4-(3-(2-(aminomethyl)acrylamido)phenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate 
• 1443236-93-8 ethyl 4-[3-({2-[(dimethylamino)methyl]acryloyl}amino)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate 
• 1443237-62-4 ethyl 4-(3-((2-((tert-butyl(dimethyl)silyl)oxy)methyl)acryloyl)amino)phenyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate 
• 1443236-95-0 ethyl 4-(3-{[2-(hydroxymethyl)acryloyl]amino}phenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate 
• 1443236-96-1 ethyl 4-(3-{[(2E)-4-(dimethylamino)but-2-enoyl]amino}phenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate 
• 1443236-97-2 ethyl 4-(3-{[(2E)-4-(dimethylamino)-2-methylbut-2-enoyl]amino}phenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate 
• 1443236-98-3 ethyl 4-(3-(2-methyloxirane-2-carboxamido)phenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate 

Relevant articles and documents

PYRROLOPYRIMIDINES AS JANUS KINASE INHIBITORS

The instant invention provides compounds of formula I which are JAK3 inhibitors. Specifically, the compounds of formula I are pyrrolo[2,3-d]pyrimidine derivative compounds. The instant invention also provides methods of treating JAK-mediated diseases such

NOVEL PYRROLOY2,3-d¨PYRIMIDINE COMPOUND

Disclosed is a novel pyrrolo[2,3-d]pyrimidine compound represented by formula [I] or a pharmacologically acceptable salt thereof, which has a GPR119 receptor agonistic activity and is useful for a pharmaceutical. In formula [I], E represents a group repre

Adenosine kinase inhibitors. 1. Synthesis, enzyme inhibition, and antiseizure activity of 5-iodotubercidin analogues

Adenosine receptor agonists produce a wide variety of therapeutically useful pharmacologies. However, to date they have failed to undergo successful clinical development due to dose-limiting side effects. Adenosine kinase inhibitors (AKIs) represent an alternative strategy, since AKIs may raise local adenosine levels in a more site- and event-specific manner and thereby elicit the desired pharmacology with a greater therapeutic window. Starting with 5-iodotubercidin (IC50 = 0.026 μM) and 5'-amino-5'- deoxyadenosine (IC50 = 0.17 μM) as lead inhibitors of the isolated human AK, a variety of pyrrolo[2,3-d]pyrimidine nucleoside analogues were designed and prepared by coupling 5-substituted-4-chloropyrrolo[2,3-d]pyrimidine bases with ribose analogues using the sodium salt-mediated glycosylation procedure. 5'-Amino-5'-deoxy analogues of 5-bromo- and 5-iodotubercidins were found to be the most potent AKIs reported to date (IC50s 0.001 μM). Several potent AKIs were shown to exhibit anticonvulsant activity in the rat maximal electric shock (MES) induced seizure assay.